---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: PI3K, AKT, and mTOR pathway inhibitors"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: PI3K, AKT, and mTOR pathway inhibitors. Topics: Guideline recommendation: NCCN, PIK3CA, AKT1, or PTEN alterations; Guideline recommendation: NCCN, everolimus combinations; Guideline recommendation: ABC8, PI3K/AKT/mTOR pathway inhibitor class; Guideline recommendation: ASCO 2021, alpelisib and everolimus; 16 further topics. 20 evidence topics quoted from 20 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/pi3k-akt-and-mtor-pathway-inhibitors"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: PI3K, AKT, and mTOR pathway inhibitors

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 PI3K, AKT, and mTOR Pathway Inhibitors

<a id="topic-2.2.2.1.2-1"></a>

### Guideline recommendation: NCCN, PIK3CA, AKT1, or PTEN alterations

> “For patients with alterations in PIK3CA/AKT1/PTEN who have disease progression on at least one endocrine-based regimen in the metastatic setting or recurrence on adjuvant endocrine therapy + CDK4/6 inhibitor, the panel recommends fulvestrant in combination with either alpelisib or capivasertib (Figures 4 and 5).”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.2-2"></a>

### Guideline recommendation: NCCN, everolimus combinations

> “Based on the evidence from the BOLERO-2 trial, the NCCN panel has included everolimus + exemestane as an option for patients who fulfill the entry criteria for BOLERO-2. Tamoxifen or fulvestrant in combination with everolimus have also been included as options. The NCCN panel also notes that if there is disease progression while on an everolimus-containing regimen, there are no data to support an additional line of therapy with another everolimus regimen (Figure 4).”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.2-3"></a>

### Guideline recommendation: ABC8, PI3K/AKT/mTOR pathway inhibitor class

> “The EPIK-B5 trial confirmed that alpelisib + fulvestrant retains meaningful activity after CDK4/6i-based therapy in PIK3CA-mutated disease (median PFS improvement of 4.6 months; HR: 0.52), consolidating this combination as a valid option in the absence of contraindications [ 36 ].”
> “Gedatolisib, a multitarget PI3K/AKT/mTOR inhibitor, showed encouraging PFS results in the VIKTORIA-1 trial, but with a demanding administration schedule and significant stomatitis burden requiring careful management [ 39 ]. The use of a PI3K/AKT/mTOR inhibitor after progression on another agent of the same class is not recommended outside clinical trials.”
> “As multiple targeted agents are now available following progression on a CDK4/6i, the optimal sequence remains undefined; until prospective comparative data are available, the eligibility criteria of individual trials and the tumor biomarker profile should guide treatment selection.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.1.2-4"></a>

### Guideline recommendation: ASCO 2021, alpelisib and everolimus

> “Alpelisib in combination with ET should be offered to postmenopausal patients in combination with fulvestrant, and to male patients, with HR-positive, HER2-negative, PIK3CA-mutated, ABC, or MBC following prior ET including an aromatase inhibitor (AI), with or without a CDK4/6 inhibitor.”
> “Thus, everolimus may be an option in second or subsequent lines of endocrine-based therapy, although the clinical benefits in contemporary practice in patients treated with CDK4/6 inhibitors are not well defined.”
> “There are no data for the use of alpelisib after everolimus, or vice versa, to guide clinical recommendations.”

Source: [Burstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8659999/)

<a id="topic-2.2.2.1.2-5"></a>

### Comparator regulatory information: capivasertib

> “TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)- positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration as detected by an FDA-authorized test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.”

Source: [Truqap prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218197s006lbl.pdf)

<a id="topic-2.2.2.1.2-6"></a>

### Capivasertib, CAPItello-291: progression-free survival

> “Overall, 708 patients underwent randomization; 289 patients (40.8%) had AKT pathway alterations, and 489 (69.1%) had received a CDK4/6 inhibitor previously for advanced breast cancer.”
> “In the AKT pathway–altered population, the median progression-free survival was 7.3 months in the capivasertib–fulvestrant group, as compared with 3.1 months in the placebo–fulvestrant group (hazard ratio, 0.50; 95% CI, 0.38 to 0.65; P<0.001).”
> “Adverse events leading to discontinuation were reported in 13.0% of the patients receiving capivasertib and in 2.3% of those receiving placebo.”

Source: [Turner et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11335038/)

<a id="topic-2.2.2.1.2-7"></a>

### Capivasertib, CAPItello-291: biomarker-negative subgroup and overall survival

> “An exploratory analysis of PFS in the 313 (44%) patients whose tumors did not have a PIK3CA/AKT1/PTEN-alteration showed a HR of 0.79 (95% CI: 0.61, 1.02), indicating that the difference in the overall population was primarily attributed to the results seen in the population of patients whose tumors have PIK3CA/AKT1/PTEN-alteration.”
> “At the prespecified final analysis of OS, there was no significant difference in OS between the TRUQAP with fulvestrant arm and the placebo with fulvestrant arm, with HR 0.83 (95% CI: 0.63, 1.10) in the PIK3CA/AKT1/PTEN-altered subgroup.”

Source: [Truqap prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218197s006lbl.pdf)

<a id="topic-2.2.2.1.2-8"></a>

### Comparator regulatory information: alpelisib

> “is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-authorized test following progression on or after an endocrine-based regimen.”
> “Overall, 60% of enrolled patients had tumors with one or more PIK3CA mutations in tissue, 50% had liver/lung metastases, and 6% had previously been treated with a CDK4/6 inhibitor.”

Source: [Piqray prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212526s011lbl.pdf)

<a id="topic-2.2.2.1.2-9"></a>

### Alpelisib, SOLAR-1: progression-free survival and toxicity

> “In the cohort of patients with PIK3CA-mutated cancer, progression-free survival at a median follow-up of 20 months was 11.0 months (95% confidence interval [CI], 7.5 to 14.5) in the alpelisib-fulvestrant group, as compared with 5.7 months (95% CI, 3.7 to 7.4) in the placebo-fulvestrant group (hazard ratio for progression or death, 0.65; 95% CI, 0.50 to 0.85; P<0.001)”
> “In the overall population, the most frequent adverse events of grade 3 or 4 were hyperglycemia (36.6% in the alpelisib-fulvestrant group vs. 0.7% in the placebo-fulvestrant group) and rash (9.9% vs. 0.3%).”
> “The percentages of patients who discontinued alpelisib and placebo owing to adverse events were 25.0% and 4.2%, respectively.”

Source: [André et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31091374/)

<a id="topic-2.2.2.1.2-10"></a>

### Alpelisib, SOLAR-1: overall survival

> “In the PIK3CA-mutated cohort (n = 341), median OS [95% confidence interval (CI)] was 39.3 months (34.1-44.9) for alpelisib-fulvestrant and 31.4 months (26.8-41.3) for placebo-fulvestrant [hazard ratio (HR) = 0.86 (95% CI, 0.64-1.15; P = 0.15)]. OS results did not cross the prespecified efficacy boundary.”

Source: [André et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33246021/)

<a id="topic-2.2.2.1.2-11"></a>

### Alpelisib after a CDK4/6 inhibitor: BYLieve

> “Patients receiving alpelisib and fulvestrant after an AI and a CDK4/6 inhibitor had a median PFS of 7.3 months and 50.4% were alive without disease progression at 6 months (n = 121).”

Source: [Burstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8659999/)

<a id="topic-2.2.2.1.2-12"></a>

### Comparator regulatory information: inavolisib (first-line, endocrine-resistant disease)

> “ITOVEBI, in combination with palbociclib and fulvestrant, is indicated for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy”

Source: [Itovebi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219249s004lbl.pdf)

<a id="topic-2.2.2.1.2-13"></a>

### Inavolisib, INAVO120: progression-free survival

> “The median progression-free survival was 15.0 months (95% confidence interval [CI], 11.3 to 20.5) in the inavolisib group and 7.3 months (95% CI, 5.6 to 9.3) in the placebo group (hazard ratio for disease progression or death, 0.43; 95% CI, 0.32 to 0.59; P<0.001).”

Source: [Turner et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39476340/)

<a id="topic-2.2.2.1.2-14"></a>

### Inavolisib, INAVO120: overall survival

> “After a median follow-up of 34.2 months in the inavolisib group and 32.3 months in the placebo group, the median overall survival was 34.0 months (95% confidence interval [CI], 28.4 to 44.8) with inavolisib and 27.0 months (95% CI, 22.8 to 38.7) with placebo (hazard ratio for death, 0.67; 95% CI, 0.48 to 0.94; P = 0.02 [prespecified boundary for statistical significance, P<0.0469]).”
> “Adverse events led to discontinuation of inavolisib in 6.8% of patients and discontinuation of placebo in 0.6%.”

Source: [Jhaveri et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13496148/)

<a id="topic-2.2.2.1.2-15"></a>

### Inavolisib: NCCN limitation on sequencing

> “A key limitation of the trial is the lack of cross-over, which is relevant because PIK3CA-pathway inhibitors are known to have significant activity in later line settings. Thus, it is unknown whether treatment with inavolisib in the first-line versus in a later line is truly superior.”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.2-16"></a>

### Comparator regulatory information: gedatolisib

> “On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.”
> “There was a statistically significant improvement in PFS for Arm A vs Arm C, with a median PFS of 9.3 months (95% CI: 7.2, 16.6) in Arm A and 2.0 months (95% CI: 1.8, 2.3) in Arm C (hazard ratio [HR] 0.24 [95% CI: 0.17, 0.35]; p-value <0.0001). There was also a statistically significant improvement in PFS for Arm B vs Arm C with a median PFS of 7.4 months (95% CI: 5.5, 9.9) in Arm B and 2.0 months (95% CI: 1.8, 2.3) in Arm C (HR 0.33 [95% CI: 0.24, 0.48]; p-value <0.0001).”
> “At the time of the PFS analysis, OS data were not mature with 25% deaths in the overall population.”

Source: [FDA gedatolisib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally)

<a id="topic-2.2.2.1.2-17"></a>

### Gedatolisib, VIKTORIA-1: safety

> “Grade ≥3 treatment-related adverse events (TRAEs) reported in the gedatolisib-triplet and gedatolisib-doublet groups, respectively, included neutropenia (62.3%, 0.8%), stomatitis (19.2%, 12.3%), rash (4.6%, 5.4%), hyperglycemia (2.3%, 2.3%), and diarrhea (1.5%, 0.8%). Study treatment discontinuation because of TRAEs was reported in 2.3% (triplet) and 3.1% (doublet) of patients.”

Source: [Hurvitz et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13075786/)

<a id="topic-2.2.2.1.2-18"></a>

### Comparator regulatory information: everolimus

> “is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole.”

Source: [Afinitor prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022334s055lbl.pdf)

<a id="topic-2.2.2.1.2-19"></a>

### Everolimus, BOLERO-2: progression-free survival and toxicity

> “The most common grade 3 or 4 adverse events were stomatitis (8% in the everolimus-plus-exemestane group vs. 1% in the placebo-plus-exemestane group), anemia (6% vs. <1%), dyspnea (4% vs. 1%), hyperglycemia (4% vs. <1%), fatigue (4% vs. 1%), and pneumonitis (3% vs. 0%).”
> “Median progression-free survival was 10.6 months and 4.1 months, respectively, according to central assessment (hazard ratio, 0.36; 95% CI, 0.27 to 0.47; P<0.001).”

Source: [Baselga et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5705195/)

<a id="topic-2.2.2.1.2-20"></a>

### Everolimus, BOLERO-2: overall survival

> “Median OS in patients receiving EVE + EXE was 31.0 months [95% confidence interval (CI) 28.0–34.6 months] compared with 26.6 months (95% CI 22.6–33.1 months) in patients receiving PBO + EXE (hazard ratio = 0.89; 95% CI 0.73–1.10; log-rank P = 0.14).”

Source: [Piccart et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/)

Additional sources: [Rugo et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39637900/); [Dilawari et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11588547/); [Burstein et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38478799/); [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
